At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,289 enrolled
Drug / intervention
Xalatan 0.005% eye dropsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Aug 3, 2009·Updated Feb 25, 2021
In Brief
An observational study evaluating Xalatan 0.005% eye drops for Glaucoma and Ocular Hypertension. Completed, enrolled 1,289 participants across 3 sites in 3 countries.
Detailed Summary
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesEgypt, Saudi Arabia, United Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
Primary CompletionDec 2007
First PostedAug 2009
TodayJul 2026
First PostedAug 3, 2009
Enrollment StartJul 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.9 years ago
Interventions
Xalatan 0.005% eye dropsdrug
ophthalmic solution dosed once daily for 3 months